Kura Oncology (NASDAQ:KURA) Stock Price Down 2.7% – Here’s What Happened

Kura Oncology, Inc. (NASDAQ:KURA)’s share price traded down 2.7% during trading on Monday . The stock traded as low as $7.69 and last traded at $7.63. 44,364 shares changed hands during trading, a decline of 96% from the average session volume of 1,057,173 shares. The stock had previously closed at $7.84.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on the stock. StockNews.com lowered shares of Kura Oncology from a “buy” rating to a “hold” rating in a research note on Tuesday, March 18th. Wedbush restated an “outperform” rating and issued a $36.00 target price on shares of Kura Oncology in a research report on Thursday, February 27th. BTIG Research cut Kura Oncology from a “buy” rating to a “neutral” rating in a research report on Thursday, February 6th. JMP Securities reaffirmed a “market outperform” rating and set a $28.00 target price on shares of Kura Oncology in a research note on Thursday, February 6th. Finally, HC Wainwright reiterated a “buy” rating and issued a $40.00 price target on shares of Kura Oncology in a research report on Thursday, February 27th. Four investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $25.50.

Kura Oncology Trading Down 2.9 %

The company has a fifty day simple moving average of $7.82 and a 200-day simple moving average of $12.38. The stock has a market cap of $614.55 million, a price-to-earnings ratio of -3.22 and a beta of 0.85. The company has a current ratio of 11.47, a quick ratio of 11.47 and a debt-to-equity ratio of 0.02.

Kura Oncology (NASDAQ:KURA) last released its quarterly earnings results on Wednesday, February 26th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.65) by $0.43. The firm had revenue of $53.88 million for the quarter, compared to analyst estimates of $57.96 million. On average, research analysts forecast that Kura Oncology, Inc. will post -2.44 earnings per share for the current fiscal year.

Insider Activity

In other Kura Oncology news, SVP Thomas James Doyle sold 4,949 shares of the company’s stock in a transaction that occurred on Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total value of $38,948.63. Following the transaction, the senior vice president now owns 88,193 shares in the company, valued at approximately $694,078.91. This represents a 5.31 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Mollie Leoni sold 4,963 shares of the firm’s stock in a transaction dated Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total value of $39,058.81. Following the sale, the insider now directly owns 88,253 shares of the company’s stock, valued at $694,551.11. This trade represents a 5.32 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 11,729 shares of company stock worth $92,307 over the last quarter. Corporate insiders own 5.50% of the company’s stock.

Hedge Funds Weigh In On Kura Oncology

A number of hedge funds have recently added to or reduced their stakes in KURA. Barclays PLC grew its position in Kura Oncology by 104.5% in the third quarter. Barclays PLC now owns 165,484 shares of the company’s stock worth $3,234,000 after acquiring an additional 84,563 shares in the last quarter. SG Americas Securities LLC bought a new stake in Kura Oncology in the fourth quarter worth $436,000. Moody Aldrich Partners LLC increased its position in Kura Oncology by 42.3% during the fourth quarter. Moody Aldrich Partners LLC now owns 143,587 shares of the company’s stock worth $1,251,000 after buying an additional 42,712 shares during the last quarter. Harbor Capital Advisors Inc. raised its holdings in Kura Oncology by 4.4% during the fourth quarter. Harbor Capital Advisors Inc. now owns 49,371 shares of the company’s stock valued at $430,000 after buying an additional 2,076 shares in the last quarter. Finally, Jennison Associates LLC acquired a new stake in shares of Kura Oncology in the fourth quarter worth about $623,000.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.